CM24 + nivolumab + nanoliposomal irinotecan + 5-fluorouracil + leucovorin

CM24 + nivolumab + nanoliposomal irinotecan + 5-fluorouracil + leucovorin is an investigational combination regimen for solid tumors, notably advanced pancreatic and gastrointestinal cancers. CM24 is a monoclonal antibody targeting CEACAM1 with immune-modulating and anti-tumor effects. Nivolumab is a programmed cell death protein 1 (PD-1) inhibitor, classified as an immune checkpoint inhibitor and used in a range of cancers to enhance T-cell antitumor response[1][5][7]. Nanoliposomal irinotecan (nal-IRI, Onivyde) is a liposome-encapsulated topoisomerase I inhibitor, designed for improved delivery and tumor retention; it is approved for metastatic pancreatic cancer[2][4][6]. 5-fluorouracil is a cytotoxic antimetabolite interfering with DNA synthesis, and leucovorin is a folate analog used to enhance the activity of 5-fluorouracil. Collectively, this combination targets immune checkpoints, cell cycle, and DNA synthesis, synergizing immunotherapy with cytotoxic chemotherapy[2][4][6]. The combination is under evaluation in clinical trials for advanced solid tumors.

Brand names

OpdivoOnivyde

Other names

CM24CM-24CM 24OpdivoOnivydefluorouracil5-FUfolinic acid